JP2023527741A5 - - Google Patents

Info

Publication number
JP2023527741A5
JP2023527741A5 JP2022570279A JP2022570279A JP2023527741A5 JP 2023527741 A5 JP2023527741 A5 JP 2023527741A5 JP 2022570279 A JP2022570279 A JP 2022570279A JP 2022570279 A JP2022570279 A JP 2022570279A JP 2023527741 A5 JP2023527741 A5 JP 2023527741A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
use according
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527741A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032808 external-priority patent/WO2021236543A1/en
Publication of JP2023527741A publication Critical patent/JP2023527741A/ja
Publication of JP2023527741A5 publication Critical patent/JP2023527741A5/ja
Pending legal-status Critical Current

Links

JP2022570279A 2020-05-19 2021-05-17 アミロイドーシスの治療 Pending JP2023527741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
US63/027,194 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (2)

Publication Number Publication Date
JP2023527741A JP2023527741A (ja) 2023-06-30
JP2023527741A5 true JP2023527741A5 (cg-RX-API-DMAC7.html) 2024-05-23

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570279A Pending JP2023527741A (ja) 2020-05-19 2021-05-17 アミロイドーシスの治療

Country Status (12)

Country Link
US (1) US20230210846A1 (cg-RX-API-DMAC7.html)
EP (1) EP4138837A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023527741A (cg-RX-API-DMAC7.html)
KR (1) KR20230013102A (cg-RX-API-DMAC7.html)
CN (1) CN116133661A (cg-RX-API-DMAC7.html)
AU (1) AU2021273731A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023486A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183746A1 (cg-RX-API-DMAC7.html)
IL (1) IL298297A (cg-RX-API-DMAC7.html)
MX (1) MX2022014468A (cg-RX-API-DMAC7.html)
TW (1) TW202207931A (cg-RX-API-DMAC7.html)
WO (1) WO2021236543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316472A (en) * 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
US20210154368A1 (en) * 2018-04-09 2021-05-27 Case Western Reserve University Bioink and crosslinkable support medium for printing
US10659731B2 (en) * 2018-04-10 2020-05-19 Facebook, Inc. Automated cinematic decisions based on descriptive models
US10526132B2 (en) * 2018-04-10 2020-01-07 Dow Global Technologies Llc Dispenser for can with fixed valve stem housing

Similar Documents

Publication Publication Date Title
JP2012532889A5 (cg-RX-API-DMAC7.html)
RU2385721C2 (ru) Комбинации, включающие антимускариновые агенты и кортикостероиды
ES2657907T3 (es) Aplicaciones terapéuticas de ectoína
JP2012528792A5 (cg-RX-API-DMAC7.html)
JP6175364B2 (ja) 子宮内膜増殖を抑制するための組成物および方法
PE20241067A1 (es) Composiciones, metodos y sistemas para la administracion de farmacos en aerosol
MA39155A1 (fr) Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol
US10456390B2 (en) Combinations comprising MABA compounds and corticosteroids
RU2018103940A (ru) Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза
HRP20180944T1 (hr) Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
BG107625A (bg) Контрацептивен метод и форми за осъществяването му
JP2006502160A5 (cg-RX-API-DMAC7.html)
SI2393477T1 (en) Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma
US5407926A (en) Ophthalmic composition
ES2247959T1 (es) Formulacion medica en aerosol estabilizada en agua.
JP2020529418A5 (ja) T細胞急性リンパ芽球性白血病を治療するための化合物、組成物及び方法
NZ574658A (en) Combination of azelastine and steroids such as fluticasone and mometasone for nasal and ocular use
WO2014131852A1 (en) Combinations comprising maba compounds and corticosteroids
JP2021534201A5 (cg-RX-API-DMAC7.html)
JP2010502736A5 (cg-RX-API-DMAC7.html)
RU2005129276A (ru) Применение стероидов для лечения субъектов, страдающих заболеванием глаз
MXPA06013850A (es) Combinaciones que comprenden agentes antimuscarinicos y corticosteroides.
Bircher et al. Contact Hypersensitivity to Corticosteroids in Routine Patch Test Patients: A Multi-Centre Study of the Swiss Contact Dermatitis Research Group
AR089839A1 (es) Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular
IL312515A (en) Bispecific cd16a binders